This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor ≤0.25 cm. HIPEC with cisplatin (CDDP) 75 mg/m 2 for 60 minutes at ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) ...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Colorectal cancer (CRC) is a prevalent and deadly disease worldwide. Around 1.9 million new cases and over 903,000 deaths were estimated in 2022. 1 In the United States, it has been projected that by ...

Cancer treatment has evolved significantly, with a growing recognition that high-quality care extends beyond treating the disease alone. Multiple guidelines emphasize the need for comprehensive person ...

Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Early-stage, triple-negative breast cancer (TNBC) is the most challenging breast cancer (BC) subtype to treat, characterized by a higher histologic grade, resulting in relatively early and high ...

Background: Neutropenia is the most common hematological toxicity of myelosuppressive chemotherapy. To observe the efficacy and safety of efbemalenograstim alfa in the prevention of absolute ...

Hepatocellular carcinoma (HCC) is a lethal malignancy that is subtle neither in its clinical presentation nor in its aggressive course. Numerous diagnostic guidelines have focused on noninvasive ...